ARWR

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals, Inc. (ARWR) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Profitability (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C
Factor Score 2.4 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -14.7
EV / EBITDA -10.2
Rev Growth YoY -85.3%
Gross Margin N/M
Price Return 3M -46.1%
Price Return 12M 15.3%
Catalyst Signal +0.14
Market Cap $6.8B
TTM Revenue $450.8M
Price / Sales 15.0
ROE -258.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (2.9) C+ (2.6) C- (2.0) C- (2.1) C (2.4) C (2.4)
2026-11-09 B- (2.9) C (2.2) C+ (2.6) C (2.3) C (2.4) C (2.5)
2026-11-02 B- (2.9) C (2.2) C+ (2.7) C (2.4) C (2.4) C+ (2.5)
2026-10-26 B- (3.0) C (2.2) C+ (2.7) C (2.3) C+ (2.8) C+ (2.6)
2026-10-19 B- (3.0) C (2.2) C+ (2.7) C+ (2.5) B- (2.9) C+ (2.7)
Page 1 of 8
…